Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature.
Yujiro MatsuishiBryan J MathisNobutake ShimojoSatoru KawanoYoshiaki InouePublished in: Vascular health and risk management (2020)
Landiolol is useful as a first-line therapy for the prevention of POAF after cardiac/non-cardiac surgery, fatal arrhythmias in heart failure patients and during PCI. Moreover, the potential therapeutic effect of landiolol for sepsis in pediatric patients is currently being explored. As positive RCT results continue to be published, new clinical uses and further clinical studies in various settings by cardiologists, intensivists and pediatric cardiologists are being conducted.
Keyphrases
- cardiac surgery
- acute kidney injury
- coronary artery disease
- acute myocardial infarction
- intensive care unit
- acute coronary syndrome
- percutaneous coronary intervention
- left ventricular
- ejection fraction
- septic shock
- antiplatelet therapy
- st elevation myocardial infarction
- randomized controlled trial
- heart failure
- systematic review
- young adults
- meta analyses